Journal of Thoracic Oncology
Издатель: Elsevier · ISSN 1556-0864 · 84 статей
- Ending Tobacco Use Without Redistributing Tobacco Harm
- Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid
- Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial
- Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance
- Weight Gain on Lorlatinib Is Associated With Accumulation of Visceral Adipose Tissue
- Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights From a Large-Scale Real-World Chinese Cohort
- Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in NSCLC
- Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial
- Phase III Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced or Metastatic NSCLC (ZEAL-1L)
- Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement
- The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the Tenth Edition TNM Classification
- Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC—The ACTIVE Trial
- Refining the Prognostic Meaning of MTAP Loss in Driver-Positive NSCLC
- A Response to the Letter to the Editor: “Refining the Prognostic Meaning of MTAP Loss in Driver-Positive NSCLC”
- Central Adiposity, Confounding Medications, and the Reinterpretation of the “Obesity Paradox” in Lung Cancer Risk
- A Response to the Letter to the Editor: “Central Adiposity, Confounding Medications, and the Reinterpretation of the “Obesity Paradox” in Lung Cancer Risk”
- A Three-Month Washout Is a Risk Marker, Not a Safety Threshold, Before Adjuvant Osimertinib
- Response to the Letter
- Brief Report: Patterns of Disease Progression with Durvalumab versus Placebo After Concurrent Chemoradiotherapy for Limited-Stage SCLC in the Phase 3 ADRIATIC Trial
- Tarlatamab for Treatment of Small Cell Lung Cancer in Clinical Practice: A Multicenter U.S. Retrospective Cohort Study from the ONWARD consortium
- Soxataltinib, a highly selective CNS-penetrant RET inhibitor demonstrates durable activity in RET fusion–positive non-small cell lung cancer phase 2 study
- Clinicogenomic determinants of early progression on first-line osimertinib in EGFR-mutant NSCLC
- Low-dose CT Screening and Smoking Cessation: Separate and Joint Associations with Mortality among Ever-Smokers Eligible for Lung Cancer Screening
- Final Analysis From PECATI Phase 2 Trial: Lenvatinib in Combination With Pembrolizumab in Pretreated Advanced B3 Thymoma and Thymic Carcinoma